Regulatory settlements and investment targets are driving biosimilar launches and facility expansion in the US.

1 report, 1 independent Updated Jul 2

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Amgen Biocon

How it developed

Newest first. Tap a step to see who reported it.

Jul 6Biocon is showing signs of a bullish technical breakout from its consolidation phase, with trading targets set above Rs 400.Sub-event
Jul 2US settlement allows biosimilar launches; ruling blocks state price cap on Enbrel.1 source
- financialcontent.com

Keep exploring

Part of

Amgen, Pfizer, and Celltrion are key players poised for rapid expansion in the biosimilars market in the US. All 1 developments

The entities involved

Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05
Biocon
an Indian biopharmaceutical company

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 2financialcontent.com